|
US7115728B1
(en)
|
1995-01-30 |
2006-10-03 |
Ligand Pharmaceutical Incorporated |
Human peroxisome proliferator activated receptor γ
|
|
EP0930882A2
(en)
*
|
1996-08-02 |
1999-07-28 |
Institut Pasteur De Lille |
Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
|
|
US6121288A
(en)
*
|
1996-11-08 |
2000-09-19 |
Nippon Chemiphar Co., Ltd. |
Visceral fat lowering agent
|
|
DE69726182T2
(de)
|
1996-12-11 |
2004-08-12 |
Dana-Farber Cancer Institute, Inc., Boston |
Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
|
|
US6586455B1
(en)
*
|
1996-12-31 |
2003-07-01 |
The Salk Institute For Biological Studies |
Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
|
|
GB9712866D0
(en)
*
|
1997-06-18 |
1997-08-20 |
Smithkline Beecham Plc |
Novel method of treatment
|
|
AU8355998A
(en)
|
1997-07-24 |
1999-02-16 |
Yamanouchi Pharmaceutical Co., Ltd. |
Medicinal compositions with cholesterol-lowering effect
|
|
WO1999005161A1
(en)
|
1997-07-25 |
1999-02-04 |
Ligand Pharmaceuticals Incorporated |
HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
|
|
FR2767058B1
(fr)
*
|
1997-08-05 |
2000-05-05 |
Centre Nat Rech Scient |
Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
|
|
AU2893199A
(en)
*
|
1998-03-03 |
1999-09-20 |
Board Of Regents, The University Of Texas System |
Fatty acid-induced beta-cell apoptosis
|
|
AU1707599A
(en)
*
|
1998-03-20 |
1999-10-18 |
Warner-Lambert Company |
Retinoid-glitazone combinations
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6191154B1
(en)
*
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
|
AU1797700A
(en)
|
1998-12-14 |
2000-07-03 |
Nuclear Receptor Research Limited |
Novel ligands of nuclear receptor
|
|
US6756360B1
(en)
|
1998-12-24 |
2004-06-29 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
|
|
US6436993B1
(en)
|
1999-07-13 |
2002-08-20 |
The Salk Institute For Biological Studies |
Use of RAR antagonists as modulators of hormone mediated processes
|
|
WO2001016120A1
(en)
|
1999-08-27 |
2001-03-08 |
Eli Lilly And Company |
Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
|
|
CA2407421C
(en)
|
2000-04-24 |
2009-11-03 |
Nikken Chemicals Co., Ltd. |
Activators of peroxisome proliferator-activated receptors
|
|
US7563774B2
(en)
|
2000-06-29 |
2009-07-21 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
|
|
US20020031539A1
(en)
*
|
2000-08-30 |
2002-03-14 |
The Brigham And Women's Hospital, Inc. |
Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
|
|
WO2002028175A2
(en)
*
|
2000-10-03 |
2002-04-11 |
Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) |
Transgenic mouse for targeted recombination mediated by modified cre-er
|
|
FR2814642B1
(fr)
|
2000-10-03 |
2005-07-01 |
Ass Pour Le Dev De La Rech En |
Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
|
|
US20030045553A1
(en)
|
2001-04-04 |
2003-03-06 |
Bussolari Jacqueline C. |
Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
|
|
JP4590158B2
(ja)
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
|
|
FR2832064A1
(fr)
*
|
2001-11-13 |
2003-05-16 |
Lipha |
Composition pharmaceutique comprenant une glitazone et un derive de thiazolidinedione et son utilisation pour traiter le diabete
|
|
TW200303742A
(en)
*
|
2001-11-21 |
2003-09-16 |
Novartis Ag |
Organic compounds
|
|
US7264813B2
(en)
|
2003-09-24 |
2007-09-04 |
Nikken Sohonsha Corporation |
Therapeutic uses of Dunaliella powder
|
|
US20080274193A1
(en)
*
|
2004-01-23 |
2008-11-06 |
Japan Science And Technology Agency |
Retinoic Acid-Containing Antidiabetic Agent
|
|
EP1737809B1
(en)
|
2004-02-27 |
2013-09-18 |
Amgen, Inc |
Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
|
|
JP4737084B2
(ja)
*
|
2004-03-12 |
2011-07-27 |
堺化学工業株式会社 |
アミド化合物、医薬組成物及びｒｘｒ機能調節剤
|
|
JP5211322B2
(ja)
*
|
2008-03-07 |
2013-06-12 |
国立医薬品食品衛生研究所長 |
ピリミジン−５−カルボン酸誘導体の抗肥満剤としての新規用途
|
|
WO2011006157A2
(en)
*
|
2009-07-10 |
2011-01-13 |
Case Western Reserve University |
Rxr agonist compounds and methods
|
|
JP5725491B2
(ja)
*
|
2010-04-14 |
2015-05-27 |
国立大学法人鳥取大学 |
レチノイン酸受容体リガンドによるインスリン抵抗性改善作用
|
|
CN105143445B
(zh)
*
|
2012-11-29 |
2020-07-07 |
宝生物欧洲公司 |
衍生自人多能干细胞的肝细胞样细胞的成熟
|
|
US9585857B2
(en)
|
2013-01-18 |
2017-03-07 |
Cornell University |
Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists
|
|
WO2015138686A1
(en)
*
|
2014-03-13 |
2015-09-17 |
J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Inducing brown fat fate and function
|